SLC35G2

Summary

SLC35G2 (solute carrier family 35 member G2, HGNC:28480) is a protein-coding gene on chromosome 3q22.3, encoding Solute carrier family 35 member G2 (Q8TBE7).

Located in Golgi apparatus; plasma membrane; and synaptic vesicle membrane.

Source: NCBI Gene 80723 — RefSeq curated summary.

At a glance

• Gene–disease (curated): mitochondrial complex I deficiency (Limited, GenCC)
• GWAS associations: 11
• Clinical variants (ClinVar): 1 total
• MANE Select transcript: NM_025246

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:28480
Approved symbol	SLC35G2
Name	solute carrier family 35 member G2
Location	3q22.3
Locus type	gene with protein product
Status	Approved
Aliases	MGC3295, DKFZp564K2464
Ensembl gene	ENSG00000168917
Ensembl biotype	protein_coding
OMIM	617812
Entrez	80723

Gene structure

Transcript identifiers

Ensembl transcripts: 12 — 11 protein_coding, 1 protein_coding_CDS_not_defined

ENST00000393079, ENST00000446465, ENST00000472200, ENST00000852766, ENST00000852767, ENST00000852768, ENST00000937922, ENST00000937923, ENST00000937924, ENST00000937925, ENST00000937926, ENST00000956989

RefSeq mRNA: 3 — MANE Select: NM_025246 NM_001097599, NM_001097600, NM_025246

CCDS: CCDS3091

Canonical transcript exons

ENST00000446465 — 2 exons

Exon	Start	End
ENSE00001682181	136819126	136819628
ENSE00001924650	136854443	136855888

Expression profiles

Bgee: expression breadth ubiquitous, 222 present calls, max score 92.40.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 8.4569 / max 75.9310, expressed in 1410 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
38748	5.7537	1325
38747	1.5343	910
38749	1.1689	640

Top tissues by expression

275 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
sperm	CL:0000019	92.40	gold quality
cartilage tissue	UBERON:0002418	91.64	gold quality
secondary oocyte	CL:0000655	91.42	gold quality
male germ cell	CL:0000015	90.61	gold quality
islet of Langerhans	UBERON:0000006	90.10	gold quality
pericardium	UBERON:0002407	88.98	gold quality
cerebellar vermis	UBERON:0004720	88.52	gold quality
oocyte	CL:0000023	88.42	gold quality
pons	UBERON:0000988	88.35	gold quality
adenohypophysis	UBERON:0002196	88.04	gold quality
pituitary gland	UBERON:0000007	87.91	gold quality
endothelial cell	CL:0000115	87.46	gold quality
cerebellum	UBERON:0002037	86.90	gold quality
cerebellar cortex	UBERON:0002129	86.82	gold quality
cerebellar hemisphere	UBERON:0002245	86.75	gold quality
ventricular zone	UBERON:0003053	86.74	gold quality
hypothalamus	UBERON:0001898	86.37	gold quality
adipose tissue	UBERON:0001013	86.10	gold quality
right hemisphere of cerebellum	UBERON:0014890	85.91	gold quality
postcentral gyrus	UBERON:0002581	85.89	gold quality
superior frontal gyrus	UBERON:0002661	85.71	gold quality
adipose tissue of abdominal region	UBERON:0007808	85.60	gold quality
omental fat pad	UBERON:0010414	85.42	gold quality
peritoneum	UBERON:0002358	85.38	gold quality
connective tissue	UBERON:0002384	85.32	gold quality
prefrontal cortex	UBERON:0000451	85.24	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	85.22	gold quality
Brodmann (1909) area 9	UBERON:0013540	85.14	gold quality
subcutaneous adipose tissue	UBERON:0002190	84.95	gold quality
frontal cortex	UBERON:0001870	84.67	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	5.28

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

31 targeting SLC35G2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-656-3P	100.00	72.15	2788
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-4262	100.00	73.26	3931
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-30A-5P	100.00	76.31	3233
HSA-MIR-30B-5P	100.00	76.29	3248
HSA-MIR-30C-5P	100.00	76.29	3248
HSA-MIR-30D-5P	100.00	76.32	3233
HSA-MIR-30E-5P	100.00	76.32	3242
HSA-MIR-223-3P	99.99	70.14	1140
HSA-MIR-34A-5P	99.99	71.21	1784
HSA-MIR-449A	99.99	71.05	1776
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-181A-5P	99.99	72.96	2995
HSA-MIR-181B-5P	99.99	72.97	2996
HSA-MIR-181C-5P	99.99	72.95	2996
HSA-MIR-181D-5P	99.99	73.04	2997
HSA-MIR-34C-5P	99.97	70.45	1577
HSA-MIR-449B-5P	99.97	70.26	1580
HSA-MIR-544A	99.84	68.66	1965
HSA-MIR-3617-5P	99.75	69.41	1968
HSA-MIR-641	99.75	69.35	1975
HSA-MIR-4524A-3P	99.72	66.85	2406
HSA-MIR-548AU-3P	99.70	68.22	1373
HSA-MIR-5197-5P	99.64	69.08	1494
HSA-MIR-20A-3P	99.44	69.10	1575
HSA-MIR-889-3P	99.40	69.76	2103
HSA-MIR-410-3P	99.27	69.98	2457
HSA-MIR-7702	99.06	65.95	698
HSA-MIR-4724-5P	98.87	67.75	1324

Literature-anchored findings (GeneRIF, showing 1)

• the TMEM22/RAB37 complex is likely to play a crucial role in growth of renal cell carcinoma (PMID:19148500)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	slc35g2b	ENSDARG00000045447
danio_rerio	slc35g2a	ENSDARG00000056262
mus_musculus	Slc35g2	ENSMUSG00000070287
rattus_norvegicus	Slc35g2	ENSRNOG00000015370
drosophila_melanogaster	CG5281	FBGN0037902

Paralogs (5): SLC35G3 (ENSG00000164729), SLC35G1 (ENSG00000176273), SLC35G5 (ENSG00000177710), SLC35G4 (ENSG00000236396), SLC35G6 (ENSG00000259224)

Protein

Protein identifiers

Solute carrier family 35 member G2 — Q8TBE7 (reviewed: Q8TBE7)

Alternative names: Transmembrane protein 22

All UniProt accessions (1): Q8TBE7

UniProt curated annotations — full annotation on UniProt →

Subunit / interactions. Interacts with RAB37.

Subcellular location. Cell membrane. Cytoplasmic vesicle. Secretory vesicle. Synaptic vesicle membrane.

Similarity. Belongs to the SLC35G solute transporter family.

RefSeq proteins (3): NP_001091068, NP_001091069, NP_079522* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000620	EamA_dom	Domain
IPR037185	EmrE-like	Homologous_superfamily

Pfam: PF00892

UniProt features (27 total): topological domain 11, transmembrane region 10, domain 2, chain 1, modified residue 1, sequence variant 1, sequence conflict 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8TBE7-F1	77.60	0.49

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 409

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 68 (showing top): HERNANDEZ_ABERRANT_MITOSIS_BY_DOCETACEL_2NM_UP, WEI_MYCN_TARGETS_WITH_E_BOX, AMIT_EGF_RESPONSE_480_MCF10A, NF1_Q6_01, chr3q22, KIM_WT1_TARGETS_12HR_UP, NRSF_01, GOCC_EXOCYTIC_VESICLE, GOCC_SECRETORY_VESICLE, GOCC_SYNAPSE, GOCC_PRESYNAPSE, GOCC_TRANSPORT_VESICLE_MEMBRANE, HAMAI_APOPTOSIS_VIA_TRAIL_UP, NOUSHMEHR_GBM_SILENCED_BY_METHYLATION, HIRSCH_CELLULAR_TRANSFORMATION_SIGNATURE_UP

GO Biological Process (0):

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (6): Golgi apparatus (GO:0005794), plasma membrane (GO:0005886), synaptic vesicle membrane (GO:0030672), membrane (GO:0016020), cytoplasmic vesicle (GO:0031410), synapse (GO:0045202)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cytoplasm	2
binding	1
endomembrane system	1
intracellular membrane-bounded organelle	1
membrane	1
cell periphery	1
synaptic vesicle	1
exocytic vesicle membrane	1
cellular anatomical structure	1
intracellular vesicle	1
cell junction	1

Protein interactions and networks

STRING

424 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
SLC35G2	SLC35F5	Q8WV83	535
SLC35G2	TMEM61	Q8N0U2	506
SLC35G2	CDC50B	Q3MIR4	476
SLC35G2	SLC35E1	Q96K37	465
SLC35G2	SLC35C1	Q96A29	459
SLC35G2	TMEM158	Q8WZ71	440
SLC35G2	TMEM25	Q86YD3	435
SLC35G2	TMEM213	A2RRL7	434
SLC35G2	RTP3	Q9BQQ7	432
SLC35G2	TMEM45A	Q9NWC5	430
SLC35G2	TMEM116	Q8NCL8	418
SLC35G2	TMEM156	Q8N614	410
SLC35G2	SLC35E3	Q7Z769	406
SLC35G2	SLC35E2A	P0CK97	406
SLC35G2	SLC35H1	Q9NQQ7	395

IntAct

36 interactions, top by confidence:

A	B	Type	Score
TMEM86B	SLC35G2	psi-mi:“MI:0915”(physical association)	0.560
FAM209A	SLC35G2	psi-mi:“MI:0915”(physical association)	0.560
	SLC35G2	psi-mi:“MI:0915”(physical association)	0.560
SLC10A6	SLC35G2	psi-mi:“MI:0915”(physical association)	0.560
AQP6	SLC35G2	psi-mi:“MI:0915”(physical association)	0.560
SLC35G2	DSCC1	psi-mi:“MI:0915”(physical association)	0.560
HTR2C	KLRG2	psi-mi:“MI:0914”(association)	0.530
MAS1	POTEF	psi-mi:“MI:0914”(association)	0.530
SLC15A1	METTL15	psi-mi:“MI:0914”(association)	0.530
SPPL2B	UQCRQ	psi-mi:“MI:0914”(association)	0.530
GRPR	GPR89A	psi-mi:“MI:0914”(association)	0.350
SLC35G2	DDX23	psi-mi:“MI:0914”(association)	0.350
C5AR1	TCAF2	psi-mi:“MI:0914”(association)	0.350
GCGR	GPR89A	psi-mi:“MI:0914”(association)	0.350
SPPL2B	GPR89A	psi-mi:“MI:0914”(association)	0.350
GPR12	TLCD2	psi-mi:“MI:0914”(association)	0.350
SLC5A6	SLC31A1	psi-mi:“MI:0914”(association)	0.350
SLC35G2	MAOB	psi-mi:“MI:0914”(association)	0.350
SLC35G2	GPR89A	psi-mi:“MI:0914”(association)	0.350
FHIP2A	MED19	psi-mi:“MI:2364”(proximity)	0.270
SLC35G2	TMEM86B	psi-mi:“MI:0915”(physical association)	0.000
SLC35G2	FAM209A	psi-mi:“MI:0915”(physical association)	0.000
SLC35G2		psi-mi:“MI:0915”(physical association)	0.000
SLC35G2	SLC10A6	psi-mi:“MI:0915”(physical association)	0.000
SLC35G2	AQP6	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (83): TGFB1 (Affinity Capture-MS), DSCC1 (Affinity Capture-MS), SLC35G2 (Affinity Capture-MS), SLC35G2 (Affinity Capture-MS), SLC35G2 (Affinity Capture-MS), SLC35G2 (Affinity Capture-MS), CHRAC1 (Affinity Capture-MS), SLC35G2 (Affinity Capture-MS), DSCC1 (Affinity Capture-MS), DDX23 (Affinity Capture-MS), SLC35G2 (Synthetic Lethality), SLC35G2 (Two-hybrid), SLC35G2 (Two-hybrid), SLC35G2 (Two-hybrid), SLC35G2 (Two-hybrid)

ESM2 similar proteins: A0A509AYF4, A5K8B0, D3YVE8, G5EBM5, J9UD11, O74921, P0C0K1, P0C0K2, P13773, P31381, P35206, P53748, Q1ZXQ7, Q4LCA6, Q4UDS9, Q54DP2, Q54ET0, Q54F25, Q54L53, Q54LG8, Q54SH8, Q54SW3, Q54U89, Q550A6, Q55AP1, Q55C66, Q55CN8, Q5A6K2, Q6CSN0, Q75JP4, Q75JT4, Q7REK3, Q7Z0V9, Q86H31, Q86HH3, Q8IBZ9, Q8IDM6, Q8SRA2, Q8SUF9, Q8SUG0

Diamond homologs: B0K004, D3YVE8, P0C7Q5, P0C7Q6, Q0Q7U7, Q0Q7U8, Q0Q7U9, Q0Q7V0, Q5F297, Q5M7A3, Q5ZJZ4, Q8N808, Q8TBE7, Q96KT7

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

1 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	1
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1074 predictions. Top by Δscore:

Variant	Effect	Δscore
3:136854442:GAATT:G	acceptor_gain	1.0000
3:136838858:T:G	donor_gain	0.9900
3:136838916:A:AG	donor_gain	0.9900
3:136838917:G:GG	donor_gain	0.9900
3:136854439:ATAG:A	acceptor_loss	0.9900
3:136854441:A:AG	acceptor_gain	0.9900
3:136854441:AGAA:A	acceptor_loss	0.9900
3:136854442:G:GG	acceptor_gain	0.9900
3:136854442:GA:G	acceptor_gain	0.9900
3:136854442:GAAT:G	acceptor_gain	0.9900
3:136854774:GGAT:G	donor_gain	0.9900
3:136838912:GCCCA:G	donor_gain	0.9800
3:136854437:A:AG	acceptor_gain	0.9800
3:136854438:A:G	acceptor_gain	0.9800
3:136854654:G:GT	donor_gain	0.9700
3:136854807:G:GT	donor_gain	0.9700
3:136838920:A:AG	donor_gain	0.9600
3:136854440:T:G	acceptor_gain	0.9600
3:136854442:GAA:G	acceptor_gain	0.9600
3:136838921:T:G	donor_gain	0.9500
3:136854556:GCCT:G	acceptor_gain	0.9500
3:136819289:GGAA:G	donor_gain	0.9400
3:136827308:TGCCC:T	donor_gain	0.9300
3:136838881:G:GT	donor_gain	0.9300
3:136819290:G:T	donor_gain	0.9200
3:136838857:GTTAG:G	donor_gain	0.9200
3:136842313:GAT:G	donor_gain	0.9200
3:136819210:CGCAG:C	donor_loss	0.9100
3:136819212:CAG:C	donor_loss	0.9100
3:136819213:AGGTA:A	donor_loss	0.9100

AlphaMissense

2712 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
3:136855145:A:C	S229R	0.999
3:136855147:C:A	S229R	0.999
3:136855147:C:G	S229R	0.999
3:136855253:G:A	G265R	0.999
3:136855253:G:C	G265R	0.999
3:136855254:G:A	G265E	0.999
3:136855343:G:T	G295W	0.999
3:136855454:T:C	F332L	0.999
3:136855456:C:A	F332L	0.999
3:136855456:C:G	F332L	0.999
3:136854806:G:A	G116R	0.998
3:136854806:G:C	G116R	0.998
3:136854975:G:A	G172D	0.998
3:136855001:T:C	C181R	0.998
3:136855076:A:C	S206R	0.998
3:136855078:T:A	S206R	0.998
3:136855078:T:G	S206R	0.998
3:136855502:A:C	S348R	0.998
3:136855504:C:A	S348R	0.998
3:136855504:C:G	S348R	0.998
3:136854807:G:A	G116E	0.997
3:136854974:G:C	G172R	0.997
3:136855251:C:A	A264D	0.997
3:136855337:T:A	W293R	0.997
3:136855337:T:C	W293R	0.997
3:136855343:G:A	G295R	0.997
3:136855343:G:C	G295R	0.997
3:136855439:T:C	C327R	0.997
3:136855460:G:A	G334R	0.997
3:136855460:G:C	G334R	0.997

dbSNP variants (sampled 300 via entrez): RS1000002543 (3:136844135 T>C), RS1000014872 (3:136834437 G>A,T), RS1000056942 (3:136830835 C>A), RS1000133801 (3:136817594 C>T), RS1000146391 (3:136850694 A>G,T), RS1000424856 (3:136820634 C>G), RS1000480691 (3:136829530 T>G), RS1000532770 (3:136829327 T>G), RS1000552725 (3:136833998 A>C,G), RS1000555204 (3:136821814 C>A), RS1000580493 (3:136850384 G>A), RS1000631126 (3:136820309 T>C), RS1000856518 (3:136854430 T>C), RS1000927173 (3:136821759 A>G), RS1001032820 (3:136829244 A>G,T)

Disease associations

OMIM: gene MIM:617812 | disease phenotypes:

GenCC curated gene-disease

Disease	Classification	Inheritance
mitochondrial complex I deficiency	Limited	Autosomal recessive

Mondo (1): mitochondrial complex I deficiency (MONDO:0100133)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

11 associations (top):

Study	Trait	p-value
GCST002539_50	Schizophrenia	7.000000e-11
GCST004521_157	Autism spectrum disorder or schizophrenia	3.000000e-08
GCST004946_94	Schizophrenia	4.000000e-15
GCST006803_84	Schizophrenia	4.000000e-12
GCST006940_20	Neurociticism	1.000000e-12
GCST007324_51	Adventurousness	5.000000e-08
GCST008058_215	Estimated glomerular filtration rate	2.000000e-12
GCST008059_187	Estimated glomerular filtration rate	2.000000e-12
GCST008129_11	Body mass index	8.000000e-09
GCST010988_116	Adult body size	2.000000e-13
GCST90002388_468	Lymphocyte count	9.000000e-17

EFO canonical traits (4, from GWAS)

EFO ID	Trait name
EFO:0007660	neuroticism measurement
EFO:0008579	risk-taking behaviour
EFO:0004340	body mass index
EFO:0004587	lymphocyte count

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
C537475	Mitochondrial complex I deficiency (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: transporter — SLC35 family of nucleotide sugar transporters

CTD chemical–gene interactions

49 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects expression, affects cotreatment, increases expression	8
Benzo(a)pyrene	affects methylation, decreases methylation, increases expression	6
sodium arsenite	increases expression	2
mercuric bromide	affects cotreatment, increases expression	2
entinostat	increases expression, affects cotreatment	2
Air Pollutants	increases abundance, increases expression, decreases expression	2
Phenylmercuric Acetate	affects cotreatment, increases expression	2
Cyclosporine	increases expression	2
Aflatoxin B1	increases expression	2
p-Chloromercuribenzoic Acid	affects cotreatment, increases expression	2
Particulate Matter	increases abundance, increases expression, decreases expression	2
aristolochic acid I	increases expression	1
FR900359	decreases phosphorylation	1
methylmercuric chloride	increases expression	1
trichostatin A	increases expression	1
beta-lapachone	increases expression	1
sulforaphane	increases expression	1
tris(1,3-dichloro-2-propyl)phosphate	increases expression	1
cupric chloride	increases expression	1
coumarin	increases phosphorylation	1
beta-methylcholine	affects expression	1
di-n-butylphosphoric acid	affects expression	1
perfluorooctane sulfonic acid	increases expression	1
cylindrospermopsin	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
abrine	increases expression	1
dorsomorphin	affects cotreatment, increases expression	1
jinfukang	decreases expression	1
NSC 689534	affects binding, increases expression	1
Resveratrol	decreases expression, affects cotreatment	1

Cellosaurus cell lines

3 cell lines: 3 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_D4F6	1321N1-SLC35G2-KO-c11	Cancer cell line	Male
CVCL_D4F7	1321N1-SLC35G2-KO-c13	Cancer cell line	Male
CVCL_TN31	HAP1 SLC35G2 (-)	Cancer cell line	Male

Clinical trials (associated diseases)

1 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT05162768	PHASE3	COMPLETED	Study to Evaluate Efficacy and Safety of Elamipretide in Subjects With Primary Mitochondrial Disease From Nuclear DNA Mutations (nPMD)